. 2022 Jun 14;29(4):570–578. doi: 10.1093/ibd/izac121

Table 2.

Decrease of SCCAI and its components after start of tofacitinib throughout the 56-day induction period.

SCAAI components	Baseline (n = 96)	Day 3 (n = 92)	Day 7 (n = 94)	Day 14 (n = 90)	Day 28 (n = 88)	Day 56 (n = 79)
SCCAI score	5.63	4.55	3.78	3.32	3.40	3.18
		<0.0001^a	<0.0001^a	<0.0001^a	<0.0001^a	<0.0001^a
Frequency day	1.18	0.93	0.86	0.66	0.60	0.61
		<0.0029^a	<0.0006^a	<0.0001^a	<0.0001^a	<0.0001^a
Rectal bleeding	1.20	0.91	0.70	0.63	0.68	0.73
		<0.0002^a	<0.0001^a	<0.0001^a	<0.0001^a	<0.0001^a
Urgency	1.36	1.21	0.95	0.89	0.91	0.81
		<0.0013^a	<0.0001^a	<0.0001^a	<0.0001^a	<0.0001^a

^aSignificance level compared to baseline.